The applications of pharmacogenomics to neurological disorders

C. Gilman, C. McSweeney, Y. Mao

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

The most common neurological disorders, including neurodegenerative diseases and psychiatric disorders, have received recent attention with regards to pharmacogenomics and personalized medicine. Here, we will focus on a neglected neurodegenerative disorder, cerebral ischemic stroke (CIS), and highlight recent advances in two disorders, Parkinson's disease (PD) and Alzheimer's diseases (AD), that possess both similar and distinct mechanisms in regards to potential therapeutic targets. In the first part of this review, we will focus primarily on mechanisms that are somewhat specific to each disorder which are involved in neurodegeneration (i.e., protease pathways, calcium homeostasis, reactive oxygen species regulation, DNA repair mechanisms, neurogenesis regulation, mitochondrial function, etc.). In the second part of this review, we will discuss the applications of the genome-wide technology on pharmacogenomics of mental illnesses including schizophrenia (SCZ), autism spectrum disorders (ASD), attention deficit hyperactivity disorder (ADHD), and obsessive compulsive disorder (OCD).

Original languageEnglish (US)
Pages (from-to)880-890
Number of pages11
JournalCurrent Molecular Medicine
Volume14
Issue number7
DOIs
StatePublished - Jan 1 2014

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'The applications of pharmacogenomics to neurological disorders'. Together they form a unique fingerprint.

Cite this